Physician profile
Arvind R Samant
NPI 1578611984
$6,103.00
in general payments reported to CMS, 2019-2025
11 companies · $803 in 2025
The $803 reported for 2025 was more than what 78% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,114 · 2020: $232 · 2021: $337 · 2022: $594 · 2023: $1,731 · 2024: $1,293 · 2025: $803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,752 · Education: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,752.19 |
| Education | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,487.57 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $1,354.62 | 2019-2025 | Lybalvi, Aristada, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $648.41 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Teva Pharmaceuticals USA, INC. | $546.10 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $349.70 | 2023-2025 | Vraylar |
| Neurocrine Biosciences, INC. | $292.42 | 2019-2021 | |
| Lundbeck LLC | $147.19 | 2022-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $113.26 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $110.98 | 2025 | Cobenfy |
| Axsome Therapeutics, INC. | $38.78 | 2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.97 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arvind Samant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.